Immunomonitoring. A. Percentages of MDSCs by two criteria. B. Percentages of Tregs. C. Changes of tumor-reactive IFN-γ+ cells (% of CD4+ or CD8+ T cells). Assay was performed as described in Methods section. D. The concentration of IL-8 in sera measured by a cytofluorometry-based ELISA system at different time points during treatment of the 8 patients.